480 related articles for article (PubMed ID: 11496812)
1. [Estrogen therapy in climacteric. Current views in an evidence-based perspective].
Nilsson K
Lakartidningen; 2001 Jul; 98(28-29):3225-8. PubMed ID: 11496812
[TBL] [Abstract][Full Text] [Related]
2. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
[TBL] [Abstract][Full Text] [Related]
3. [Historical perspective of hormone replacement therapy].
Chanson P
Rev Prat; 2005 Feb; 55(4):369-75. PubMed ID: 15828614
[TBL] [Abstract][Full Text] [Related]
4. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
5. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study.
Li C; Samsioe G; Lidfelt J; Nerbrand C; Agardh CD;
Menopause; 2000; 7(4):273-81. PubMed ID: 10914621
[TBL] [Abstract][Full Text] [Related]
6. [The story of the reversal of opinion about hormone replacement therapy and cardiovascular disease].
Løkkegaard EC
Ugeskr Laeger; 2005 Mar; 167(10):1166-70. PubMed ID: 15810574
[No Abstract] [Full Text] [Related]
7. [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].
Magnusson C; Weiderpass E
Lakartidningen; 2001 Jan; 98(5):418-21. PubMed ID: 11229082
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia.
Dick SE; DeWitt DE; Anawalt BD
Am J Manag Care; 2002 Jan; 8(1):95-104; quiz 105-6. PubMed ID: 11814176
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone therapy and the risk of cardiovascular disease.
Stramba-Badiale M
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
[TBL] [Abstract][Full Text] [Related]
12. Controversies in HRT.
Teede HJ
Aust Fam Physician; 2002 May; 31(5):413-8. PubMed ID: 12043543
[TBL] [Abstract][Full Text] [Related]
13. Justification for the use of HRT in the long-term prevention of osteoporosis.
Stevenson JC
Maturitas; 2005 Jun; 51(2):113-26. PubMed ID: 15917151
[TBL] [Abstract][Full Text] [Related]
14. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life.
Franke HR; Brood-van Zanten MM; Burger CW; van der Mooren MJ; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):143-6. PubMed ID: 17574325
[TBL] [Abstract][Full Text] [Related]
16. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
Emons G; Westphalen S
MMW Fortschr Med; 2002 Feb; 144(9):30-3. PubMed ID: 11921648
[TBL] [Abstract][Full Text] [Related]
17. Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies.
Andersson K; Pedersen AT; Mattsson LA; Milsom I
Acta Obstet Gynecol Scand; 1998 Oct; 77(9):909-16. PubMed ID: 9808379
[TBL] [Abstract][Full Text] [Related]
18. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
van de Weijer PH; Mattsson LA; Ylikorkala O
Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
[TBL] [Abstract][Full Text] [Related]
19. Current trends in hormone replacement therapy.
Khashoggi TY
Saudi Med J; 2002 May; 23(5):495-502. PubMed ID: 12070567
[TBL] [Abstract][Full Text] [Related]
20. [Inconveniences and risks of untreated menopause. Benefits brought by the replacement hormonal treatment].
Drapier-Faure E
Rev Fr Gynecol Obstet; 1992; 87(7-9):393-6. PubMed ID: 1332177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
